IL101928A0 - Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules - Google Patents

Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Info

Publication number
IL101928A0
IL101928A0 IL101928A IL10192892A IL101928A0 IL 101928 A0 IL101928 A0 IL 101928A0 IL 101928 A IL101928 A IL 101928A IL 10192892 A IL10192892 A IL 10192892A IL 101928 A0 IL101928 A0 IL 101928A0
Authority
IL
Israel
Prior art keywords
bdnf
treatment
motor neuron
molecules
members
Prior art date
Application number
IL101928A
Other languages
English (en)
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of IL101928A0 publication Critical patent/IL101928A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Water Treatment By Sorption (AREA)
  • Medicines Containing Plant Substances (AREA)
  • External Artificial Organs (AREA)
IL101928A 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules IL101928A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
IL101928A0 true IL101928A0 (en) 1992-12-30

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101928A IL101928A0 (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Country Status (20)

Country Link
EP (2) EP0755682A1 (fr)
JP (1) JPH06509094A (fr)
CN (1) CN1065768C (fr)
AT (1) ATE202939T1 (fr)
AU (2) AU675409B2 (fr)
CA (1) CA2113083A1 (fr)
DE (1) DE69231930T2 (fr)
DK (1) DK0593516T3 (fr)
ES (1) ES2157903T3 (fr)
FI (1) FI940098A (fr)
GR (1) GR3036776T3 (fr)
HU (1) HUT70275A (fr)
IE (1) IE921602A1 (fr)
IL (1) IL101928A0 (fr)
NO (1) NO940084L (fr)
PT (1) PT100501A (fr)
RU (1) RU94016525A (fr)
SK (1) SK2694A3 (fr)
WO (1) WO1993001300A1 (fr)
ZA (1) ZA923639B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509600A (ja) * 1992-06-12 1995-10-26 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン−４発現に基づく治療および診断法
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
EP1278537B1 (fr) * 2000-05-05 2009-01-14 The Research Foundation Of the City university of New York Compositions de stimulation de la regeneration et de la reparation du systeme nerveux par regulation de l'activite de l'arginase 1 et de la synthese des polyamines
WO2006055685A2 (fr) * 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation de cellules neurales humaines pour traiter des troubles neurodegeneratifs
WO2008156418A1 (fr) * 2007-06-19 2008-12-24 Astrazeneca Ab Procédé de criblage ou de diagnostic du syndrome de post-poliomyélite et de la fibromyalgie
WO2009023540A1 (fr) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
WO2014111525A2 (fr) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl Nouvelles polythérapies pour le traitement de maladies du système nerveux
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
WO2023164311A2 (fr) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) et de troubles associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
CA2113083A1 (fr) 1993-01-21
GR3036776T3 (en) 2002-01-31
DE69231930T2 (de) 2002-04-11
FI940098A0 (fi) 1994-01-10
WO1993001300A1 (fr) 1993-01-21
NO940084L (no) 1994-03-08
EP0593516A1 (fr) 1994-04-27
EP0755682A1 (fr) 1997-01-29
FI940098A (fi) 1994-03-10
CN1065768C (zh) 2001-05-16
IE921602A1 (en) 1993-01-13
DK0593516T3 (da) 2001-09-17
SK2694A3 (en) 1995-02-08
PT100501A (pt) 1993-09-30
ZA923639B (en) 1993-02-24
HU9400063D0 (en) 1994-06-28
AU2009592A (en) 1993-02-11
ES2157903T3 (es) 2001-09-01
JPH06509094A (ja) 1994-10-13
CN1071585A (zh) 1993-05-05
HUT70275A (en) 1995-09-28
AU7067696A (en) 1997-01-16
NO940084D0 (no) 1994-01-10
AU675409B2 (en) 1997-02-06
ATE202939T1 (de) 2001-07-15
RU94016525A (ru) 1996-06-10
EP0593516B1 (fr) 2001-07-11
EP0593516A4 (fr) 1995-01-18
DE69231930D1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
ZA923639B (en) Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
EP0305967A3 (en) Conjugates of cytokines with immunoglobulins
AU6909091A (en) Neurologic agents for nasal administration to the brain
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
HUT47432A (en) Process for correcting disorders of immun-complexes of the circulation systhem and monocytes with double-line dns
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
AU7426487A (en) Method of treating depression using d-fenfluramine
Gordon The relationship between language and behaviour.
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
Aurela A systematic storytelling therapy.
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
Dienstfrey Neal Miller, the dumb autonomic nervous system, and biofeedback.
Repo The holistic approach to rehabilitation: a commentary
ROBINSON Comments on Ethical Protocol
AU6725387A (en) Drugs for the treatment and cure of all infectious diseases caused by pathogenic virulent micro-organisms